Journal: Frontiers in Oncology

Article Title: Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm

doi: 10.3389/fonc.2022.925818

Figure Lengend Snippet: Clinical Response of BCMA CAR T Cell Therapies in Multiple Myeloma.

Article Snippet: bb21217 ( ) , Bristol Myers Squibb/bluebird bio , CRS 1%, neurotoxicity 4% , 75% , ORR: 69%; ≥VGPR: 58%; sCR/CR: 28% , estimated median DOR: 27.2 m.

Techniques:

Journal: Experimental Hematology & Oncology

Article Title: Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing

doi: 10.1186/s40164-023-00402-5

Figure Lengend Snippet: Single-cell sequencing reveals heterogeneous changes in the BM microenvironment of CD45 + cells in R/R-MM patients before and relapse after BCMA CAR-T cell therapy. A Single cell sequencing and analysis fluency chart. B The UMAP projection of CD45 + BM cells of the patients at baseline and progression, including T cells, B/plasm cells, NK cells, monocytes/macrophages, DCs, neutrophils, and HSCs. C The UMAP plots of the patients at baseline and progression. D Dot plot of differentially expressed genes in each cluster. E The UMAP plot of CD14, CD68, and LYZ expression of monocytes/macrophages. F The UMAP plot of FCGR3B and CXCR2 expression of neutrophils. G The UMAP plot of IGHM and CD79A expression of B/plasma cells. H The UMAP plot of CD3D and CD3E expression of T cells. I The UMAP plot of NKG7 and GZLY expression of NK cells. J The UMAP plot of CD1C and MRC1 expression of DC cells. K All the cell type proportions of R/R-MM patients at baseline and progression

Article Snippet: BCMA CAR-T cell therapy in combination with targeting macrophage therapeutics may be a novel treatment option to prolong the survival time of R/R-MM patients [ ].

Techniques: Sequencing, Expressing, Clinical Proteomics

Journal: Experimental Hematology & Oncology

Article Title: Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing

doi: 10.1186/s40164-023-00402-5

Figure Lengend Snippet: BCMA positive and negative relapses occur concurrently in at relapse after BCMA CAR-T cell therapy in R/R-MM. A The UMAP plots of B/plasma cells at baseline and progression. B Dot plot of differentially expressed genes in each cluster. C The proportions of B/plasma cells of all the clusters at baseline and progression. D The violin diagram of BCMA, CD38, CD24, SLAMF7, CD138, and GPRC5D expression in each B/plasma cell cluster. E The proportion of plasma cell cluster at baseline and progression. F The enrichment of KEGG pathway in each cluster of B/plasma cells

Article Snippet: BCMA CAR-T cell therapy in combination with targeting macrophage therapeutics may be a novel treatment option to prolong the survival time of R/R-MM patients [ ].

Techniques: Clinical Proteomics, Expressing

Journal: Experimental Hematology & Oncology

Article Title: Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing

doi: 10.1186/s40164-023-00402-5

Figure Lengend Snippet: A significant increase in exhausted T cells at relapse after BCMA CAR-T cell therapy in R/R-MM. A The tSNE plots of T cells at baseline and progression. B The heatmap of differentially expressed genes in each cluster. C The proportions of T cells of all the clusters at baseline and progression. D The UMAP plots of CD8 + TemRA, exhausted CD8 + T cells, memory T cells, Naive T cells, Tregs, CD4 + TemRA, and Tc17 at baseline and progression. E The heatmap of differentially expressed genes of CD8 + TemRA, exhausted CD8 + T cells, memory T cells, Naive T cells, Tregs, CD4 + TemRA, and Tc17. F The proportion of CD8 + TemRA, exhausted CD8 + T cells, memory T cells, Naive T cells, Tregs, CD4 + TemRA, and Tc17 at baseline and progression

Article Snippet: BCMA CAR-T cell therapy in combination with targeting macrophage therapeutics may be a novel treatment option to prolong the survival time of R/R-MM patients [ ].

Techniques:

Journal: Experimental Hematology & Oncology

Article Title: Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing

doi: 10.1186/s40164-023-00402-5

Figure Lengend Snippet: A significant increase in TIGIT + NK cells at relapse after BCMA CAR-T cell therapy in R/R-MM. A The tSNE plots of NK cells at baseline and progression. B The heatmap of differentially expressed genes in each cluster. C The proportions of NK cells of all the clusters at baseline and progression. D Dot plot of TIGIT and CD69 expression in each cluster. E The violin diagram of TIGIT expression in each cluster

Article Snippet: BCMA CAR-T cell therapy in combination with targeting macrophage therapeutics may be a novel treatment option to prolong the survival time of R/R-MM patients [ ].

Techniques: Expressing

Journal: Experimental Hematology & Oncology

Article Title: Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing

doi: 10.1186/s40164-023-00402-5

Figure Lengend Snippet: Interferon-induced neutrophils increases significantly at relapse after BCMA CAR-T cell therapy in R/R-MM. A The tSNE plots of neutrophils at baseline and progression. B Dot plot of differentially expressed genes in each cluster. C The proportions of neutrophils of all the clusters at baseline and progression. D The violin diagram of IFITM3, IFITM2, IFIT3, IFIT2, ISG20, ISG15, IFI16, IFITM1, IRF1, CD24, and MMP8 expression in each cluster

Article Snippet: BCMA CAR-T cell therapy in combination with targeting macrophage therapeutics may be a novel treatment option to prolong the survival time of R/R-MM patients [ ].

Techniques: Expressing

Journal: Experimental Hematology & Oncology

Article Title: Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing

doi: 10.1186/s40164-023-00402-5

Figure Lengend Snippet: Monocytes/macrophages display tumor-promoting phenotypes and induced exhausted T cells at relapse after BCMA CAR-T cell therapy in R/R-MM. A The tSNE plots of monocytes/macrophages at baseline and progression. B The heatmap of differentially expressed genes in each cluster. C proportions of monocytes/macrophages of all the clusters at baseline and progression. D–F Dot plots of differentially expressed genes in each cluster

Article Snippet: BCMA CAR-T cell therapy in combination with targeting macrophage therapeutics may be a novel treatment option to prolong the survival time of R/R-MM patients [ ].

Techniques:

Journal: Heliyon

Article Title: Emerging Gene-editing nano-therapeutics for Cancer

doi: 10.1016/j.heliyon.2024.e39323

Figure Lengend Snippet: List of CRISPR/Cas9 based clinical trials for anti-cancer therapy as of Sep 2023, arranged according to their last date of update.

Article Snippet: TRAC KO CAR at TRAC locus β2M KO , Allogenic anti-BCMA – CAR-T cells , Relapsed/Refractory Multiple Myeloma , Electroporation , Phase I, Active, not recruiting. , 26 , 04244656 , CRISPR Therapeutics. , July 2018 , [ ] .

Techniques: CRISPR, Clinical Proteomics, Electroporation, Plasmid Preparation, Infection